AC Immune exec Joerg Hornstein to join Lundbeck as CFO

Danish CNS specialist Lundbeck (LUND: CO) said on Friday it has has appointed Joerg Hornstein as chief financial officer (CFO) and member of its executive management. He will assume the role no later than September 1, 2022, and he will be registered with the Danish Business Authority.

Mr Hornstein will join Lundbeck from AC Immune (Nasdaq: ACIU), a clinical-stage biopharmaceutical company specialized in precision medicine to diagnose, treat and prevent neurodegenerative diseases, headquartered in Lausanne, Switzerland, where he currently serves as executive vice president and CFO.

“Following a thorough internal and external search, we are delighted to welcome Joerg to Lundbeck. He brings extensive experience in delivering results and creating value across increasingly complex financial roles in Merck KGaA, Unternehmensgruppe Theo Mueller, and most recently as CFO of AC Immune. Joerg has a strong mix of understanding of neuroscience and pharma, exceptional operational experience across multiple functions and countries and demonstrated ability to lead through business transformations. The insights he has gained by leading across cultures and through periods of significant change, will be valuable in ensuring Lundbeck continues to be well positioned for sustainable, long-term value creation in the years ahead,” said Deborah Dunsire, chief executive of Lundbeck.